Dental caries and periodontal disease among people who use drugs: a systematic review and meta-analysis

Mohsen Yazdanian1, Bahram Armoon1*, Alireza Noroozi2, Rasool Mohammadi3, Amir-Hosein Bayat4, Elahe Ahounbar4, Peter Higgs5, Hormoz Sanaei Nasab6, Azadeh Bayani7 and Morteza Hemmat4

Abstract

Background: The aim of our study was to perform a systematic review of the literature and meta-analysis in order to investigate relationship between drug use and oral health.

Methods: We searched for studies in English published before July 1, 2019 on PsycINFO, PubMed, SciELO, Scopus, and Web of Science. We assessed the relationship between drug use (methamphetamines, heroin; opiates; crack, cocaine and cannabis as dependent variables) and reported tooth loss, periodontal disease, or decayed, missing, and filled teeth index as an independent variable. The data were analyzed using Stata 12.0 software.

Results: We initially identified 1836 potential articles (with 1100 duplicates) and screened the remaining 736 titles and abstracts, comprising 54 studies. In the next step, we evaluated the full-texts; 44 studies were excluded, accordingly. In total, we included 10 publications in the meta-analysis. Drug type was associated with periodontal disease (OR 1.44; 95% CI 0.8–2.6) and pooled estimates showed that type of drug used increased the odds of the number of decayed, missed and filled teeth (DMFT) (OR 4.11; 95% CI 2.07–8.15) respectively.

Conclusions: The analytical challenges of segregating the impact of individual drug types on oral health diseases mean that investigations on the direct relationship between oral health status and drug use are limited. Developing programs to improve potential confounding with various substances and addressing the dental health needs of people who use drugs is vital if we are to improve their overall quality of life.

Keywords: Oral health index, Periodontal disease, DMFT, Drug use

Background

Problematic and dependent drug use is associated with economic and social problems and is often associated with a range of medical complications [1]. The most commonly used illicit drugs globally are cannabis, opioids and stimulants [2]. The criminalization of drug use has serious public health consequences that adversely impact on the global community [3–5]. Previous studies have highlighted the negative health consequences of some drugs for people who use them [6–8]. In relation to oral health specifically, there is evidence that people who use drugs (PWUD) have a high sugar intake [9, 10]. Several studies indicate that exposing to long term drug usage are more susceptible to high intake of sugar [11, 12]. According to these studies individuals who had chronic intake of drugs such as opioid showed higher intake of sugary food and less complex carbohydrates, fruits, vegetables and fats from fish [9, 13] and do not seek help when symptoms of swelling and pain appear in their mouth [14]. Different drugs can affect the soft and hard tissues of the mouth may result in malignant states or could predispose people to oral infections [15]. Caries are one of the most serious diseases of the mouth and can be prevented using prophylactic and protective methods [16]. The caries risk factors studied in clinics and the medical practitioner evaluates signs and symptoms of salivary
hypofunction, dietary practices and measures of oral hygiene [17].

Saliva and its components are considered as effective protective endogenous agents [16], with hyposecretion of saliva by salivary glands being one of the most critical factors that increase the risk of caries [18]. Furthermore, there are the higher prevalence of periodontal diseases in methamphetamine (MA) users and some variables such as xerostomia, high carbohydrate diet, and poor oral hygiene [19, 20], endocrine dysfunction and decreased body immunity [21] are involved in poor oral and dental disease in the users. Also, several lines of evidence showed pathologic damages in oral hard and soft tissues among PWUD and these pathologic changes correlate to the higher prevalence of caries with the certain substances [22–25]. Some studies indicated that drugs such as MA have a negative effects on oral health [26, 27], and two studies reported that there was no impact [17, 28]. It seems MA use causes destructive dental caries. Some studies have suggested that it may be the physical or chemical qualities of MA or its components, such as their toxicity or acidity, directly attacking physical structure of tooth [29]. Other investigations showed that MA leads to dry mouth which decreases protective functions of saliva and mucus [26, 30, 31]. Furthermore, dental caries might happen secondary to prolonged drug-use and associated health behaviors has been attributed to salivary malfunction, poor oral hygiene, and consumption of refined carbohydrates [32]. According to a systematic review of MA use and health outcomes among adolescents, there is insufficient evidence of an association between dental outcomes and MA use [33]. Nonetheless, another study showed higher rates of dental disease among adult people who use MA [34]. In fact, dental disease as one of the most important comorbidities in PWUD is a reasons to develop treatment plans that address both oral health problems and drug use [34]. Also, one applicable index for assessing the condition of dental and oral health is the number of decayed, missed and filled teeth (DMFT) and this index comprises the number of decayed, missing, and filled teeth in a person [35]. Moreover, studies investigating oral health status have reported DMFT as a scientifically accepted index to elucidate the condition of dental and oral health [16, 18, 22, 36–39]. Thus, the aim of our study was to perform a systematic review of the literature and meta-analysis in order to investigate relationship between drug use and oral health condition.

Methods
We followed the items that were preferred for Systematic Reviews and Meta-Analyses (PRISMA) guideline for conducting the current systematic review study [40].

The questions of the systematic review
We considered the below questions for this aim:

Is there an association between drug type and oral health conditions (DMFT and periodontal disease) among PWUD?
Considering relevant MeSH terms on the basis of PICO model and in accordance with the questions specified in advance, we conducted our search strategy, as follows:
(a) P: Methamphetamine Users; heroin users; opiate users; crack users; (b) I: people who use drugs; (c) C: people who do not use drugs; (d) O: DMFT/periodontal disease.

The detailed search for each specific database can be found in Table 1.

Inclusion and exclusion criteria
Original cross-sectional and longitudinal prospective and retrospective observational studies were included. Studies compared PWUD with people who do not use drugs (PWDNUD) in terms of oral health conditions (DMFT/periodontal disease). The representativeness of the sample as well as adequacy of power for determining statistical significance could be ensured by either clarifying the representativeness of sample (e.g., the representativeness of the sub-sample of a national study) or providing sample selection details. Studies of other specific samples, such as psychiatric populations, and people who use alcohol or smoke tobacco were excluded from the study. We excluded qualitative research studies, in vitro investigations, animal studies, reviews, case reports and series, letters to editor, and congress abstracts.

Outcome measure
Studies that reported the effect of using a specific type of drug use on oral health conditions (DMFT/periodontal disease).

Definitions/criteria considered for PWUD
We included articles on illicit drug use (i.e. methamphetamines, heroin, opiates, cocaine, cannabis and crack) based-on self-report measures or interviews.

Definitions/criteria considered for oral health conditions
We only included oral diseases considered as public health issues with a global burden. As a result, investigations reporting tooth loss, periodontal disease, or DMFT as an outcome were included in the review.

We evaluated this by two most frequently used indexes in the epidemiological researches which consisted of the DMFT: the number of decayed, missing and filled teeth and the DMFS: the number of decayed, missing and filled surfaces. In the DMFT score the unit for measuring is every tooth, while for the DMFS is dental surface. Frontal teeth have four surfaces, while the back teeth have five. Hence the maximum DMFT achieves 32 (but
Table 1 search strategy

| Database       | Key words                                                                 |
|----------------|---------------------------------------------------------------------------|
| PsycINFO       | ("Drug abuse" OR "drug use OR inject drug use OR Methamphetamine user OR Cannabis users OR Heroin users OR Marijuana users OR Opiate users OR Amphetamines users or Cocaine users or Hallucinogens users") AND ("Dental Caries" OR "Periodontal Diseases" OR "Periodontitis" OR "DMF Index" OR "Tooth Loss" OR "Edentulism" OR "Dental Status" OR "Oral Health") |
| Scielo         | Drug abuse [Title words] or drug use [Title words] or inject drug use [Title words] or Methamphetamine users [Title words] or Cannabis users [Title words] or Heroin users [Title words] or Marijuana users [Title words] or Opiate users [Title words] or Amphetamines users [Title words] or Cocaine users [Title words] or Hallucinogens users [Title words] AND Oral health [Title words] or Dental Caries [Title words] or periodontal [Title words] or DMF Index [Title words] or oral hygiene [Title words] or decayed, missed and filled teeth [Title words] or tooth Loss [Title words] or "Edentulism" [Title words] or "Dental Status" [Title words] or "Oral Health" [Title words] |
| Pubmed         | #22 Search (((((((((Substance-Related Disorders[MeSH Terms]) OR Substance Abuse, Intravenous[MeSH Terms]) OR drug use[Title]) OR inject drug use[Title]) OR Methamphetamine user[Title]) OR Cannabis users[Title]) OR Heroin users[Title]) OR Marijuana users[Title]) OR Opiate users[Title]) OR Cocaine [Title]) OR Hallucogen [Title]) OR Amphetamines users[Title]) AND (((((((Dental Caries[MeSH Terms]) OR Periodontal Diseases[MeSH Terms]) OR Periodontitis[MeSH Terms]) OR DMF Index[MeSH Terms]) OR Tooth Loss[MeSH Terms]) OR Edentulism[Title]) OR Dental Status[Title]) OR Oral Health[MeSH Terms]) OR Oral Hygiene Index[MeSH Terms] |
|                | #23 Search (((((Dental Caries[MeSH Terms]) OR Periodontal Diseases[MeSH Terms]) OR Periodontitis[MeSH Terms]) OR DMF Index[MeSH Terms]) OR Tooth Loss[MeSH Terms]) OR Edentulism[Title]) OR Dental Status[Title]) OR Oral Health[MeSH Terms]) OR Oral Hygiene Index[MeSH Terms] |
|                | #24 Search ((((((Substance-Related Disorders[MeSH Terms]) OR Substance Abuse, Intravenous[MeSH Terms]) OR drug use[Title]) OR inject drug use[Title]) OR Methamphetamine user[Title]) OR Cannabis users[Title]) OR Heroin users[Title]) OR Marijuana users[Title]) OR Opiate users[Title]) OR Amphetamines users[Title] |
|                | #19 Search Oral Hygiene Index[MeSH Terms] |
|                | #18 Search Oral Health[MeSH Terms] |
|                | #17 Search Dental Status[Title] |
|                | #16 Search Edentulism[Title] |
|                | #15 Search Tooth Loss[MeSH Terms] |
|                | #14 Search DMF Index[MeSH Terms] |
|                | #13 Search Periodontitis[MeSH Terms] |
|                | #12 Search Periodontal Diseases[MeSH Terms] |
|                | #11 Search Dental Caries[MeSH Terms] |
|                | #10 Search Amphetamines users[Title] |
|                | #9 Search Opiate users[Title] |
|                | #8 Search Marijuana users[Title] |
|                | #7 Search Heroin users[Title] |
|                | #6 Search Cannabis users[Title] |
|                | #5 Search Methamphetamine user[Title] |
|                | #4 Search inject drug use[Title] |
|                | #3 Search drug use[Title] |
|                | #2 Search Substance Abuse, Intravenous[MeSH Terms] |
|                | #1 Search Substance-Related Disorders[MeSH Terms] |
| Scopus         | (TITLE-ABS-KEY (drug AND abuse) OR TITLE-ABS-KEY (drug AND use) OR TITLE-ABS-KEY (inject AND drug AND use) OR TITLE-ABS-KEY (amphetamine AND user) OR TITLE-ABS-KEY (cannabis AND users) OR TITLE-ABS-KEY (heroin AND users) OR TITLE-ABS-KEY (marijuana AND users) OR TITLE-ABS-KEY (opiate AND users) OR TITLE-ABS-KEY (amphetamine AND users) AND TITLE-ABS-KEY (dental AND caries) OR TITLE-ABS-KEY (periodontal AND diseases) OR TITLE-ABS-KEY (periodontitis) OR TITLE-ABS-KEY (dmf AND index) OR TITLE-ABS-KEY (tooth AND loss) OR TITLE-ABS-KEY (edentulism)) OR TITLE-ABS-KEY (dental AND status) OR TITLE-ABS-KEY (oral AND health)) |
| Web of Knowledge | TS = (Substance-Related Disorders OR Substance Abuse, Intravenous OR drug use OR inject drug use OR Methamphetamine user OR Cannabis users OR Heroin users OR Marijuana users OR Opiate users OR Amphetamines users) AND TS = (Dental Caries OR Periodontal Diseases OR Periodontitis OR DMF Index OR Tooth Loss OR Edentulism OR Dental Status OR Oral Health OR Oral Hygiene Index) |
| Cochrane       | #1 MeSH descriptor: [Substance-Related Disorders] explode all trees |
|                | #2 MeSH descriptor: [Substance Abuse, Intravenous] explode all trees |
|                | #3 (“drug use”):ti,ab,kw |
|                | #4 (inject drug use):ti,ab,kw |
|                | #5 (Methamphetamine user):ti,ab,kw |
|                | #6 (Cannabis users):ti,ab,kw |
|                | #7 (Heroin users):ti,ab,kw |
|                | #8 (Marijuana users):ti,ab,kw |
|                | #9 (Opiate users):ti,ab,kw |
|                | #10 (Amphetamines users):ti,ab,kw |
|                | #11 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 |
|                | #12 MeSH descriptor: [Dental Caries] explode all trees |
|                | #13 MeSH descriptor: [Periodontal Diseases] explode all trees |
|                | #14 MeSH descriptor: [Periodontitis] in all MeSH products |
we often do not consider wisdom teeth, considering the maximum 28), while the maximum DMFS is 148 (or 128 if we don’t consider wisdom teeth) [41].

Periodontal disease is defined the chronic inflammation of the supporting structures of the teeth. It occurs as gingivitis which is reversible demolishing related to the gingiva and may cause to the periodontitis. Irreversible demolishing of the gingiva, bone and periodontal ligaments that hold teeth in place. The stage of it is computed by a manual probe to evaluate pocket probing depth (PPD) or clinical attachment level (CAL) [42]. While the threshold of PPD more than 3 mm or CAL of more than 2 mm are for periodontitis [43], other researchers indicate that the threshold for PPD should be considered 4 mm [44]. Generally, if more than 4–5 mm of bone around a tooth is lost, the tooth will be increasingly movable until it falls out. In the evaluation, a PPD of 4–5 mm is considered as a ‘shallow’ pocket, although ‘deep’ pockets are 6 mm or higher [45].

All studies included clinical measures or participant self-reports showing the presence of oral diseases. It is worth noting that we selected the most severe oral health condition in the presence of several oral disease categories. Edentulism and tooth loss were assessed individually. Moreover, we excluded investigations on dysfunction temporomandibular, erosion, or xerostomia. As noted above all qualitative studies focusing on dental outcomes, including the agreement between the two authors (BA and AB). We applied the unweighted kappa to evaluate the inclusion criteria (96% agreement). For the quality assessment, we applied the unweighted kappa to evaluate the agreement between the two authors (BA and AB). We represented the levels of agreement including poor, slight, fair, moderate, substantial and complete by the values of 0, 0.01–0.02, 0.021–0.04, 0.041–0.06, 0.061–0.08, and 0.081–1.00, respectively [46].

**Search strategy and study selection**

We searched studies in English languages published before July 1, 2019 on PsycINFO, PubMed, SciELO, Scopus, and Web of Science. Table 1 describes search strategies in terms of each database. The surveyed references were managed in EndNote X7 software (Thomson Reuters, New York, NY, USA). We excluded duplicate identified studies. Two independent reviewers (AB and BA) investigated the titles and abstracts, in accordance with the inclusion and exclusion criteria of the study. Any disagreements were discussed by the two reviewers until consensus reached. A third (AMB) person from research team provided input as needed. Then, these reviewers reviewed the full-texts, observing the inclusion and exclusion criteria. Apart from the aforementioned electric search, a manual search of the reference lists was conducted on all the included studies.

**Data extraction and quality assessment**

Data items were extracted from each selected study included the first author’s name and publication year, sample characteristics, location, and design of the study, as well as data on the exposure and outcomes variables. In addition, we recorded confounding factors, effect measure, performed adjustments, and statistical methods. We contacted the relevant authors and made necessary clarifications, if necessary. The reviewers independently employed previously defined worksheets for obtaining the required data. In the first step, the reviewers observed and omitted the duplicated title and abstract which had 89% agreement according to the criteria one through three explained below. In the second step titles/abstracts met these defined criteria were selected to full-text review according to the inclusion criteria (96% agreement). For the quality assessment, we applied the unweighted kappa to evaluate the agreement between the two authors (BA and AB). We represented the levels of agreement including poor, slight, fair, moderate, substantial and complete by the values of 0, 01–0.02, 0.021–0.04, 0.041–0.06, 0.061–0.08, and 0.081–1.00, respectively [46].

**Assessment of risk of Bias in included studies**

We surveyed the included studies with respect to the quality of their methodology applying the Critical Appraisal Checklist for observational studies by The Joanna Briggs Institute (JBI) [47]. There are 10-item tool consisting of “Yes,” “No,” or “Unclear” options for cohort, case-control studies, and 8-items for cross-sectional studies answered by reviewers. The total score of each study equals to the total number of ‘yes’ answers, ranging 0–10. We classified the publications as: low quality (0–3 scores); medium quality (4–6 scores); and high quality (7–10 scores). The same reviewers independently conducted the data extractions and quality survey; any disagreements were solved through discussion (Tables 2, 3 and 4).

**Statistical analysis**

An individual meta-analysis was conducted for each oral disease. An independent analysis was also performed on

---

**Table 1: search strategy (Continued)**

| Database | Key words |
|----------|-----------|
| #15 MeSH descriptor: [DMF Index] explode all trees |
| #16 MeSH descriptor: [Tooth Loss] explode all trees |
| #17 “edentulism”ti,ab,kw |
| #18 (Dental Status):ti,ab,kw |
| #19 MeSH descriptor: [Oral Health] explode all trees |
| #20 MeSH descriptor: [Oral Hygiene Index] explode all trees |
| #21 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 |
| #22 #11 AND #21 |
| Items for critical appraisal | Were the criteria for inclusion in the sample clearly defined? | Yes | No | Unclear | Not applicable |
|------------------------------|---------------------------------------------------------------|-----|----|---------|----------------|
| Were the study subjects and the setting described in detail? | Yes | No | Unclear | Not applicable |
| Was the exposure measured in a valid and reliable way? | Yes | No | Unclear | Not applicable |
| Were objective, standard criteria used for measurement of the condition? | Yes | No | Unclear | Not applicable |

| Studies                  | Yes | No | Unclear | Not applicable |
|--------------------------|-----|----|---------|----------------|
| Rooban et al. [48]       | ✓   | ✓  |         |                |
| Reece [49]               | ✓   | ✓  |         |                |
| Kayal et al. [50]        | ✓   | ✓  |         |                |
| D'Amore et al. [51]      | ✓   | ✓  |         |                |
| Gupta et al. [52]        | ✓   | ✓  |         |                |
| Items for critical appraisal | Rooban et al. [48] | Reece [49] | Kayal et al. [50] | D'Amore et al. [51] | Gupta et al. [52] |
|-----------------------------|------------------|-------------|------------------|-------------------|------------------|
| Were confounding factors identified? | Yes | Yes | Yes | Yes | Yes |
| Were strategies to deal with confounding factors stated? | Yes | Yes | Yes | Yes | Yes |
| Were the outcomes measured in a valid and reliable way? | Yes | Yes | Yes | Yes | Yes |
| Was appropriate statistical analysis used? | Yes | Yes | Yes | Yes | Yes |
| Overall appraisal | Included moderate | Included High | Included moderate | Included High | Included moderate |
| Quality of the evidence | Yes | Yes | Yes | Yes | Yes |
| Items for critical appraisal | Were the two groups similar and recruited from the same population? | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | Was the exposure measured in a valid and reliable way? | Were confounding factors identified? | Were strategies to deal with confounding factors stated? | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? |
|-----------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------|--------------------------------|------------------------------------------------|------------------------------------------------|
| Thomson et al. [53]         | √                                                                  | √                                                                                        | √                                           | √                             | √                                             | √                                             |

Table 3: Risk of bias assessment using JBI’s critical appraisal tools for cohort studies.
| Items for critical appraisal | Were the outcomes measured in a valid and reliable way? | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | Were strategies to address incomplete follow up utilized? | Overall appraisal | Quality of the evidence |
|-----------------------------|------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------------------------------------------|-----------------|------------------------|
| studies                     | Yes No Unclear Not applicable                        | Yes No Unclear Not applicable                                                      | Yes No Unclear Not applicable                                                   | Yes No Unclear Not applicable                    |                 |                        |
| Thomson et al. [53]         | √××××                                            | √××××                                                                              | √××××                                                                            | ××××                                             | Included High  |                        |
### Table 4 Risk of bias assessment using JBI’s critical appraisal tools for case-control studies

| Studies                        | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | Were cases and controls matched appropriately? | Were the same criteria used for identification of cases and controls? | Was exposure measured in a standard, valid and reliable way? | Was exposure measured in the same way for cases and controls? | Were confounding factors identified? |
|-------------------------------|-------------------------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------|
|Mario et al. [27]              | √                                                                                              | √                                             | √                                                                   | √                                                               | √                                                               | √                             |
|Shetty et al. [54]             | √                                                                                              | √                                             | √                                                                   | √                                                               | √                                                               | √                             |
|Rommel et al. [55]             | √                                                                                              | √                                             | √                                                                   | √                                                               | √                                                               | √                             |
|Nives Protrka et al [24]       | √                                                                                              | √                                             | √                                                                   | √                                                               | √                                                               | √                             |
| Items for critical appraisal | Were strategies to deal with confounding factors stated? | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | Was the exposure period of interest long enough to be meaningful? | Was appropriate statistical analysis used? | Overall appraisal | Quality of evidence |
|-----------------------------|--------------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------|------------------------------------------|------------------|------------------|
| Morio et al. [27]           | √                                                     | √                                                     | √                                                             | √                                         | Included High    |                  |
| Shetty et al. [54]          | √                                                     | √                                                     | √                                                             | √                                         | Included High    |                  |
| Rommel et al. [55]          | √                                                     | √                                                     | √                                                             | √                                         | Included High    |                  |
| Nives Protrka et al. [24]   | √                                                     | √                                                     | √                                                             | √                                         | included moderate|                  |
studies where more than 2 variables of interest were presented. The adjusted data were considered in the meta-analysis. In other cases, we considered or calculated crude result estimates. The present study applied Odds Ratio (OR) for measuring the effect size with 95% confidence interval (CI). We converted the studies’ relative risk measures to ORs [56]. In order to calculate pooled ORs, we used fixed- and random-effects models. In addition, random-effects model was selected in case heterogeneity was observed [57]. Using $I^2$ statistic ($I^2$ of greater than 50%), heterogeneity was measured. The effect of each study on the pooled data were observed using sensitivity analysis. Eventually, the obtained data were analyzed in Stata 12.0 software (Stata Corp, College Station, TX, USA) and R 3.5.1 with the “meta” package was applied to conduct the meta-analysis.

**Results**

**Study selection**

Initial screening identified 1836 potential articles (with 1100 duplicates) by the electronic database searches. We then screened 736 titles and abstracts, with 54 studies being included. In the next step, we evaluated the full-texts of the manuscripts and 44 studies were excluded. In total, we included 10 publications in the final meta-analysis. Figure 1 represents PRISMA statement-based inclusion criteria of the study.

**Study characteristics**

Table 5 list the most important aspects of the included studies in the meta-analysis, with respect to the correlations between publications.
Synthesis of results/meta-analysis

Periodontal disease compared to drug type used

In our meta-analysis we considered 5 studies evaluating the relationship between drug type and periodontal disease [48, 50, 51, 53, 55]. These studies described the relationship between drug type as an exposure variable and periodontal disease as an outcome variable. These studies were conducted between 2008 to 2016, the sample sizes were from 57 to 1015 with a high quality structured approach. Four studies were implemented in high-income country (such as USA, Germany, New Zealand, Saudi Arabia) [50, 51, 53, 55], and the study of Rooban et al. [48] was completed in India. The three of considered studies used cross-sectional analysis [48, 50, 51], one of them was a cohort study [53] and the last one used case-control design [55] and evaluated drug type using a self-report questionnaire. Regarding the oral health measure, the five studies applied bleeding on probing index (BOP) and periodontal screening index (PSI). Pursuant to pooled estimate, type of drug used was related with periodontal disease (OR 1.44; 95% CI 0.8–2.6) (Fig. 2). Five studies statistically monitored the analyses for potential confounders. Begg’s test found no publication bias (1.83, \( P = 0.62 \)) or funnel plot analysis for periodontal status were existed. (Fig. 3).

DMFT index compare to drug type used

Seven studies [24, 27, 48, 49, 52, 54, 55] examined the relationship between the type of drug used and DMFT index among PWUD. Five studies were conducted in high-income countries [24, 27, 49, 54, 55], and two in a low middle-income country (India) [48, 52]. The date of studies ranged from 2007 to 2016, and the sample sizes were between 8 and 571. All had high quality approaches and three studies were categorized as having moderate quality of evidence. Four studies used a case-control approach for their analysis [24, 27, 54, 55] and three studies used cross-sectional design [48, 49, 52].

The results demonstrated a positive relationship on the pooled estimate for type of drug used as an exposure variable for DMFT index. The specific type of drug of used showed 4.11 times higher odds of DMFT index (OR 4.11; 95% CI 2.07–8.15) (Fig. 4). For potential confounders all studies included in this study statistically monitored their analyses. In the final model there was

Table 5 Main characteristics of the studies selected for the systematic review and meta-analysis with oral health as exposure 2019

| Study                        | Drug used by participants      | Sample size | Year | Country       | Design       | Quality of the evidence |
|------------------------------|--------------------------------|-------------|------|---------------|--------------|------------------------|
| Morio et al. [27]            | Methamphetamine users         | 18          | 2008 | USA           | Case-control | High                   |
| Shetty et al. [54]           | Methamphetamine users         | 571         | 2016 | USA           | Case-control | High                   |
| Rommel et al. [55]           | Methamphetamine users         | 200         | 2016 | Germany       | Case-control | High                   |
| Thomson et al. [53]          | Cannabis users                | 1015        | 2008 | New Zealand   | Cohort       | High                   |
| Nives Protrka et al. [24]    | Heroin users                  | 200         | 2013 | Croatia       | Case-control | Moderate               |
| Rooban et al. [48]           | Heroin and Cannabis users     | 100         | 2008 | India         | Cross-section| Moderate               |
| Reece [49]                   | Opiate users                  | 233         | 2007 | Australia     | Cross-section| High                   |
| Kayal et al. [50]            | Amphetamines                  | 57          | 2014 | Saudi Arabia  | Cross-section| Moderate               |
| D’Amore et al. [51]          | Opioid and Marijuana users    | 563         | 2011 | USA           | Cross-section| High                   |
| Gupta et al. [52]            | Illicit drug users            | 126         | 2012 | India         | Cross-section| Moderate               |

Fig. 2 Pooled effect of type of drug use on periodontal status. CI confidence interval
heterogeneity of 90.5% among studies. There was no available body of facts presenting the publication bias in Begg’s funnel plot and Egger’s test (1.65, $P = 0.11$) (Fig. 5).

**Discussion**

Prior empirically-based investigations and case studies have explored the relationship between oral health status and specific illicit drugs; however, our review of the literature resulted in no previous meta-analysis on this topic among PWUD. As a result, the current research assessed available empirical and clinical data with regard to the correlation between illicit drugs and significant oral conditions such as dental caries and periodontal disease among PWUD. Previous studies identified dental caries as the most prevalent condition among PWUD [19, 58]. Moreover, dental caries are more prevalent and severe among people who use MA, when compared to non-drug using controls [19, 55, 59]. According to a study among people who use MA in United States, untreated dental caries and the odds of having dental caries were respectively two and four times higher among cases, compared to the controls (i.e., National Health and Nutrition Examination Survey (NHANES) control group) [54]). In addition, the odds of reporting decayed, missing, or filled teeth were double among people who use MA, compared to the NHANES participants [29]. Consistent with the prior research, the mean scores of tooth decay (TD), missing teeth (MT) and DMFT were higher in the patients self-reporting drug use, in comparison to people who do not use drugs [19, 55, 59].

It could be assumed that people who use MA overlook their oral health status, given the significantly lower number of FT and higher DT scores in former MA users [60]. Another prevalent oral health problem among PWUD is periodontal disease. The corresponding
reference data in the third Chinese National Epidemiological Sampling Survey of Oral Health was lower than the findings in respect of the frequency of periodontal pockets and deep periodontal pocket, and gingival bleeding in former users of crystal MA [61].

In addition, consistent with prior research, the obtained mean score of CPI was high in people who use MA [27]. The longer the duration of drug use, the greater the risk for oral health problems [62–64]. This is while the obtained scores of DT, DMFT and CPI were significantly greater in patients reporting ≥4 years of MA use, in comparison to individuals who reported shorter history of such use. This finding is in line with previous studies. In other words, the shorter the history of MA use, the better the status of oral health, including caries and periodontal diseases would be. There are major differences between the lifestyle of patients with drug use disorders and the general population. Overlooking oral health/hygiene status is prevalent among PWUD [19, 20, 55, 65–67]. Brushing teeth more than two times a day was significantly associated with lower TD score, compared to “regularly brushing” teeth [68]; this outcome highlights the importance of specific oral health education in people who use MA. Prior research suggests a strong association between poor oral hygiene and dental caries among people who report MAuse [19, 20]. Analyzing the individual components of the mean value of DMFT indicated the mean frequency of tooth decay shaped the significant part of index. This result reveals the necessity of dental treatment for PWUD. Also, the frequency of filled teeth was significantly lower in PWUD suggesting comprehensive dental care was rarely provided to this group. Such data show that PWUD not only suffer from poor oral health status and its associated complications, but they also fail to easily access affordable oral health care services. It is worth noting that the pharmacological effects of some drugs may mask the symptoms of caries and that PWUD may self-medicate in the face of severe pain [69].

Consistent with previous research, it was found that the risk of developing caries is significantly greater in patients with chronic MA use. However, few cases were identified suffering from “meth mouth syndrome” where the typical symptoms of rampant caries at labial and a proximal surfaces [70, 71]. Case reports that applied clinical assessments along with radiography provided more accurate results and may be the reason for the great frequency of carious lesions documented in comparison with these data. These findings are in line with the previous data suggesting a higher frequency of oral health problems among PWUD [17, 72, 73].

A previous study has documented perceived poor oral health perception and drug use as correlated [74, 75]. In addition, feelings of embarrassment and low self-esteem induced by unsatisfactory oral health were common among people using MA. The literature review identified perceived oral health as important in health-related quality of life [76, 77]. Considering the aforementioned findings, addressing the particular oral health concerns of people who use MA is important. Oral health services could improve the self-esteem of their MA patients in the form of the basic behavioral-based treatments alongside dental care.
The prevalence of periodontal disease was unexpectedly high among study participants. The prevalence of total periodontitis in the US general adult population aged 35–49 years is 37% [78]; however, more than 89% of the people who use MA reported total periodontitis. The severe periodontal disease risk indicators among MA users were consistent with the data obtained from the general US population; however, these studies differ in other dimensions. The severe periodontal disease risk was greater in older and African-American individuals in this cohort study people who use MA, which is expectable in the general US population. This is while smoking and education (a proxy for socioeconomic status) were not significantly correlated with severe periodontal disease in the MA cohort. However, these are considered as significant risk factors for the general US population. In addition, there was no significant correlation between the current status of smoking and severe periodontitis under the condition of controlling sociodemographic risk factors and MA use severity; however, the same variable had a relationship with root caries and untreated anterior dental caries. The reason for such associations remains unclear; concurrent cigarette smoking among people who use MA may implicate risk-promoting behaviors for dental caries. Some examples of such behaviors are smoking as the route of MA administration or sugar-sweetened beverages intake both which lead to generating tooth decay [79]. Considering the above-mentioned points, there is a high risk for generating moderate to severe periodontitis among PWUD; however, such correlation has been overlooked by scholars. Thomson et al. [53] investigated the relationship between periodontal diseases and cannabis smoking, and recognized cannabis use as an independent risk factor for developing periodontal diseases. The prevalence of poor oral health and severe periodontal diseases have been reported to be high among people who use heroin [79, 80]. It was also found that there is a strong correlation between greater attachment loss and heroin use in comparison with other drug types. Khocht et al., found no statistically significance relationship between attachment loss and cocaine use [81] but the difference might be explained by the small number of cocaine-dependent individuals in the study. Prior research on MA has focused on the so called ‘meth mouth’ condition with limited attention to other periodontal conditions. The obtained data revealed increased attachment loss among people who use MA, compared to the general population; however, the correlation was not statistically significant. Some factors related to lifestyle such as poor nutrition, oral hygiene, and limited access to dental care may affect periodontal health status in PWUD [82–84]. According to prior research [80], the periodontal health status of patients with drug use disorders is poor. Such complication may be due to concomitant heavy use of tobacco and poor oral hygiene among them. In this regard, different substances (especially opiates) negatively effect cell division; as a result, they tilt the balance towards tissue breakdown and impair its repair and regeneration [49].

The limitations of our systematic review include the exclusion of studies on homeless populations and studies of other high-risk communities, such as people hospitalized for mental health problems or people who suffer from periodontal diseases. Moreover, we recommend assessing the studies considering the population who were mentioned above, because the high risk population may have different risk factors. Furthermore, most of the included studies were cross-sectional and this may restrict causal and temporal deduction on the relationship between oral diseases and drug use. This meta-analyses may enhance the statistical inference of analyses and are discussed as reliable sources of evidence. Another limitation is that a few studies investigated the association between dental caries and drug use, emphasizing this gap in the literature. Also, since we did not interfere with the setting of independent and dependent variables, we had to report only the data that were published in the articles. Although the associations of any systemic disorders, age and Psychological condition with increased prevalence of caries among PWUDs were necessary for suitable interventions but only one paper reported the association between the age and periodontal diseases, none of them reviewed the relationship between psychological condition and any systemic disorders with any systemic disorders and therefore we could not report it in our results because of the few numbers of them. The strengths of our study include the number of high quality studies reviewed with a large representative sample and multivariate analysis regulating for potential confounders. These factors provided greater statistical power and strengthening the results of the reviewed studies and enhancing the chance of recognizing a true effect of exposure [85].

Conclusions
To the best of our knowledge, this is the first meta-analysis evaluating oral health in PWUD and the present study provides important data regarding significantly higher levels of dental health problems among PWUD. Screening for oral health disease in drug treatment settings could increase early detection of oral health problems and facilitate referral to dental care services. Our study identified poor DMFT and caries and periodontal diseases among PWUD which may be explained by irregular tooth brushing and a long history of drug use. There is evidence to show that it is possible to treat caries and periodontal complications among PWUD by
linking substance treatment programs with oral hygiene services. Addressing dental health issues among PWUD is vital, and despite the analytical challenges of segregating the direct impact of drug use on oral health morbidities. The data highlight the need for developing affordable and accessible prevention programs that improve the oral health status among PWUD by the policymakers and public health authorities.

Abbreviations
BOP: Bleeding on probing; CI: Confidence interval; DMFT: Decayed, missing and filled teeth; IBI: The Joanna Briggs Institute; MA: Methamphetamine; MT: Missing teeth; NHADES: National Health and Nutrition Examination Survey; OR: Odds Ratio; PRISMA: Preferred for Systematic Reviews and Meta-Analyses; PSI: Periodontal screening index; PWDNUD: People who do not use drugs; PWUD: People who use drugs; TD: Tooth decay

Acknowledgments
The authors would like to acknowledge the contributions of Mehdi Noroozi to the work of this review of evidence.

Authors’ contributions
Study design: BA and AB. Database searched, data extraction and data synthesis: BA, MR, RM, and EA. Initial manuscript draft: BA, EA, and AHB. Critical revision of the manuscript: MY, PH, AN and HSN. All authors read and approved the final version of the manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not Applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Research Center for Prevention of Oral and Dental Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR, Iran. 2Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran. 3Department of Public Health, Lorestan University of Medical Sciences, Khoram Abad, Iran. 4Social Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran. 5Department of Public Health, School of Psychology and Public Health, La Trobe University, Melbourne, Australia. 6Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. 7Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: 9 August 2019 Accepted: 15 January 2020
Published online: 10 February 2020

References
1. Deegenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70.
2. Chinwood DD, Sanchez J, Comerford M, McCoy CB. Primary preventive health care among injection drug users, other sustained drug users, and non-users. Subst Use Misuse. 2001;36(6):7180–23.
3. DeBeck K, Cheng T, Montaner JS, Beyrer C, Elliott R, Sherman S, Wood E, Baral S. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. Lancet HIV. 2017;4(8):e357–74.
4. Noroozi M, Ahounbar E, eddin Karimi S, Ahmedi S, Najafi M, Barzafshan a, Shushtari ZJ, Farhadi MH, Higgs P, Rezaei F: HIV risk perception and risky behavior among people who inject drugs in Kermanshah, Western Iran. Int J Behav Med. 2017;24(4):613–8.
5. Armoorn B, Noroozi M, Jorjoran Shushtari Z, Shahsani A, Ahounbar E, Karimi S, Ahmedi S, Farhoudian A, Rahmani A, Abbasi M. Factors associated with HIV risk perception among people who inject drugs: findings from a cross-sectional behavioral survey in Kermanshah, Iran. Int J Subst Use. 2018;23(1):63–6.
6. Hoggatt KJ, Frayne SM, Saechao FS, Yano EM, Washington DL. Substance use disorder-related disparities in patient experiences of Primary Care. Health Equity. 2019;3(1):193–7.
7. Noroozi M, Noroozi A, Sharifir H, Harouni GG, Marshall BD, Ghisvand H, Qorbani M, Armoorn B. Needle and syringe programs and HIV-related risk behaviors among men who inject drugs: a multilevel analysis of two cities in Iran. Int J Behav Med. 2019;26(1):50–8.
8. Noroozi M, Marshall BD, Noroozi A, Armoorn B, Sharifir H, Farhoudian A, Ghisvand H, Vameghi M, Rezaei O, Sayadnassir M. Do needle and syringe programs reduce risky behaviours among people who inject drugs in Kermanshah City, Iran? A coarsened exact matching approach. Drug Alcohol Rev. 2018;37(5):303–8.
9. ZADOR D, WALL PML, WEBSTER I. High sugar intake in a group of women on methadone maintenance in South Western Sydney, Australia. Addiction. 1996;91(7):1053–61.
10. MORABIA A, FABRE J, GHEE E, ZEGER S, ORSAT E, ROBERT A. Diet and opiate addiction: a quantitative assessment of the diet of non-institutionalized opiate addicts. Br J Addict. 1989;84(2):173–80.
11. Kolarzyk E, Chrostek JM, Pach D, Janik A, Kwiatkowski J, Szkurkowski M. Assessment of daily nutrition ratios of opiate-dependent persons before and after 4 years of methadone maintenance treatment. Przegläd lekarski. 2005;62(6):638–72.
12. Mysels DJ, Sullivan MA. The relationship between opioid and sugar intake: review of evidence and clinical applications. J Opioid Manag. 2010;6(6):145–52.
13. Nolan LJ, Scagnelli LM. Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Subst Use Misuse. 2007;42(10):1555–66.
14. Santolaria-Fernández FJ, Gómez-Srivent JL, González-Reimers CE, Batista-López J, Jorge-Hernández J, Rodríguez-Moreno F, Martínez-Riera A, Hernández-García MT. Nutritional assessment of drug addicts. Drug Alcohol Depend. 1995;38(1):11–8.
15. Thavarajah R, Rao A, Raman U, Rajasekaran ST, Joshua E. R H, Kannan R. Oral lesions of 500 habitual psychoactive substance users in Chennai, India. Archives Oral Biol. 2006;51(8):512–9.
16. Pereira AC, Da Cunha FL. Meneghini MDS, Wemer CW. Dental caries and fluorosis prevalence study in a nonfluoridated Brazilian community: trend analysis and toothpaste association. ASDC J Dent Child. 2000;67(2):132–7.
17. Brown C, Krishnan S, Hursh K, Yu M, Johnson P, Page K, Shiboski CH. Dental disease prevalence among methamphetamine and heroin users in an urban setting a pilot study. J Am Dent Assoc. 2012;143(9):902–1001.
18. Leung WK, Chu CH. Dental caries and periodontal status of 12-year-old school children in rural Qinghai, China. Int J Dent. 2003;53(2):73–8.
19. Shetty V, Mooney LJ, Zigler CM, Belin TR, Murphy D, Rawson R. The relationship between methamphetamine use and increased dental disease. J Am Dent Assoc. 2010;141(3):307–18.
20. Murphy DA, Harrell L, Fintzy R, Vitero S, Gutierrez A, Shetty V. Soda consumption among methamphetamine users in the US: impact on Oral Health. Oral Health Prev Dentistry. 2016;14(3):277.
21. In SW, Son E-W, Rhee D-K, Pyo S. Methamphetamine administration produces immunomodulation in mice. J Toxic Environ Health. 2005;68(23–24):1233–45.
22. Tapotba H, Bakayoko-Ly R. Oral health status of 12-year-old schoolchildren in the province of Kadio, Burkina Faso. Community Dent Health. 2000;17(1):38–40.
23. Drugs UNOo, Crime. World drug report 2010. Australia: United Nations Publications; 2010.
24. Nives P, Marina K, Irlis F, Zeljko V. Varies prevalence in heroin addicts. Acta Clinica Croatica. 2013;52(4):436–43.
25. Leone CW, Oppenheim FG. Physical and chemical aspects of saliva as indicators of risk for dental caries in humans. J Dent Educ. 2001;65(10):1054–7.
26. Ravenel MC, Salinas CF, Marlow NM, Slate EH, Evans ZP, Miller PM. Methamphetamine abuse and oral health: a pilot study of “meth mouth”. Quintessence Int. 2012;43(3):229–37.
27. Morio KA, Marshall TA, Qian F, Morgan TA. Comparing diet, oral hygiene and caries status of adults who use methamphetamine with non-users – a pilot study. J Am Dent Assoc. 2008;139(2):171–6.

28. Cretzmeyer M, Walker J, Hall JA, Arndt S. Methamphetamine use and dental disease: results of a pilot study. J Dent Child. 2007;74(2):85–92.

29. Mallatt ME, J Subst Abuse Treat. 2011;41(2):179–185.

30. Garcia-Godoy F, Hicks MJ. Maintaining the integrity of the enamel surface: the role of dental biofilm, saliva and preventive agents in enamel demineralization and remineralization. J Am Dent Assoc. 2008;139:255–345.

31. Saini TS, Edwards PC, Kimmes NS, Carroll LR, Shaner JW, Dowd FJ, Saini T, Kimmes NS. Etiology of xerostomia and dental caries among methamphetamine abusers. Oral Health Prev Dentistry. 2005;3(3):189–95.

32. Colon P Jr. Dental disease in the narcotic addict. Oral Surg Oral Med Oral Pathol. 1972;33(6):905–10.

33. Marshall BDL, Web D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction. 2010(108):991–1002.

34. Shetty V, Harrell L, Murphy Debar A, Vitero S, Gutierrez A, Bellin TR, Dye BA, Spolsky JW. Dental disease patterns in methamphetamine users: findings in a large urban sample. J Am Dent Assoc. 2015;146(12):875–85.

35. Sadat Sajadi F, Moradi M, Pardakhty A, Yazdizadeh R, Madani F. Effect of chlorhexidine gluconate mouthwash on salivary Streptococcus mutans count and the prevalence of Oral side effects. J Dent Res Clin Dent Pract. 2015;9(1):49–52.

36. Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, Mess C. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):2–37.

37. Narbutaitė V, Vehkalahti MM, Milčius V, Milčius E. Dental fluorosis and dental caries among 12-year-old children from high- and low-fluoride areas in Lithuania. Eur J Oral Sci. 2007;115(2):137–42.

38. Ghaffari M, Rahshanderou S, Ramezan Khani A, Buunk-Werkhoven Y, Noroozi M, Armoon B. Are educating and promoting interventions effective in oral health? A systematic review. Int J Dent Hyg. 2018;16(1):48–58.

39. Ghaffari M, Rahshanderou S, Ramezan Khani A, Noroozi M, Armoon B. Oral health education and promotion programmes: meta-analysis of 17-year intervention. Int J Dent Hyg. 2018;16(1):59–67.

40. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. In:; 2010.

41. Do L, Roberts-Thomson K. Dental caries experience in the Australian adult population; 2007.

42. AcCò S, Marques A, Pannuti CM, RFL M, Lotufo-Neto F. Evaluation of periodontitis in hospital outpatients with major depressive disorder. J Periodontal Res. 2014;49(1):77–84.

43. Savage A, Eaton KA, Molés DR, Needleman I. A systematic review of definitions of periodontitis and methods that have been used to identify this disease. J Clin Periodontol. 2009;36(6):656–67.

44. Savage A, Eaton KA, Molés DR, Needleman I. A systematic review of definitions of periodontitis and methods that have been used to identify this disease. J Clin Periodontol. 2009;36(6):458–67.

45. Albandar JM. Epidemiology and risk factors of periodontal diseases. Dental Clinics. 2005;49(3):517–32.

46. Lands JK, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.

47. Moola S, Kinsman A, Atkin LS, Currie C, MacPhee J, Qureshi R, Mallett S, Lisy K, M. P.F.: Chapter 7: Systematic reviews of etiology and risk. The Joanna Briggs Institute. https://reviewersmanual.joannabriggs.org/; 2017.

48. Rooban T, Rao A, Joshua E, Ranganathan K. Dental and oral health status in drug abusers in Chennai, India: a cross-sectional study. J Oral Maxillofacial Pathol. 2008;12(1):16.

49. Reece A. Dentition of addiction in Queensland: poor dental status and major contributing drugs. Aust Dent J. 2007;52(2):144–9.

50. Kaya RA, Elias WY, Alharthi AK, Mandurah JM. Illicit drug abuse affects periodontal health status. Saud Med J. 2014;35(7):724–8.

51. D’Amore MM, Cheng DM, Kressin NR, Jones J, Samet JH, Winter M, Kim TW, Satz R. Oral health of substance-dependant individuals: impact of specific substances. J Subst Abuse Treat. 2011;41(2):179–85.

52. Gupta T, Shah N, Mathur V, Dhawan A. Oral health status of a group of illicit drug users in Delhi, India. Community Dent Health. 2012;29(1):49.

53. Thomson WM, Poulton R, Broadbent JM, Moffitt TE, Caspi A, Beck JD, Welch D, Hancox RJ. Cannabis smoking and periodontal disease among young adults. Jama. 2008;299(5):525–31.
84. Cho C, Hirsch R, Johnstone S. General and oral health implications of cannabis use. Aust Dent J. 2005;50(2):70–4.
85. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14(5):365.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.